Kaposi's sarcoma. An Update.

Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Kaposi's sarcoma. An Update.

Dermatol Surg. 1996 Mar;22(3):274-87. Unique Identifier : AIDSLINE MED/96178091
Zalla MJ; Department of Dermatology, Mayo Clinic Scottsdate, AZ 85259, USA.

Abstract: BACKGROUND: Kaposi's sarcoma (KS) had been an uncommon entity prior to the outbreak of the AIDS epidemic but is now the most common neoplasm occurring in patient's with AIDS. KS occurs in four distinct subsets, each of which the dermatologist is well suited to diagnose and manage. Significant advances have been made recently related to the etiology of KS and new options for treatment. OBJECTIVE: The purpose of this paper is to update clinicians on the diagnosis, etiology, and treatment of KS. METHODS: Articles from the recent dermatologic and nondermatologic literature have been reviewed and summarized. RESULTS: The clinical features of the four subsets of KS are presented. Recent evidence reveals a close association between KS and a new human herpesvirus, termed Kaposi's sarcoma-associated herpesvirus (KSHV), in all subsets of KS. KSHV may play an etiologic role in the development of some cases of KS. Treatment options include local destructive measures and systemic regimens, the choice of which is based on extent of disease, symptomatology, degree of immunosuppression, and concurrent medical problems. New treatments aimed at factors involved in the pathogenesis of KS may provide additional options for the future. CONCLUSION: KS is a disease well suited to diagnosis and management by dermatologists. As more is learned of its etiology and pathogenesis, new therapeutic approaches will continue to be developed.

Keywords: Acquired Immunodeficiency Syndrome/COMPLICATIONS Adult Aged Combined Modality Therapy Female Human HIV-1 Male Middle Age Sarcoma, Kaposi's/*DIAGNOSIS/EPIDEMIOLOGY/ETIOLOGY/THERAPY Skin Neoplasms/*DIAGNOSIS/EPIDEMIOLOGY/ETIOLOGY/THERAPY JOURNAL ARTICLE REVIEW REVIEW, ACADEMIC
960730
M9670515

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .